AstraZeneca hikes full-year forecast as Nexium holds its own, Brilinta delivers

Tracy Staton

has so far weathered the patent cliff well enough to actually raise its full-year sales for 2015. Its growth strategy appears to be paying off. But the U.K.-based company faces another big hurdle in the advent of Crestor generics–and investors aren't letting up on the pressure.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS